Business Wire

Mobile Industry Backs GSMA Embedded SIM Specification to Benefit from US$1.1 Trillion Internet of Things Opportunity

Del

The GSMA today announced that Indosat, Tele2 and Telefónica | Vivo are the latest mobile operators to launch commercial solutions based on the GSMA Embedded SIM Specification for the remote over-the-air provisioning of machine-to-machine (M2M) devices such as smart meters or connected cars. The Embedded SIM Specification is now backed by 23 mobile operators, including members of the Global M2M Association (GMA) and the M2M World Alliance, and 11 operators worldwide have launched commercial solutions.¹ The adoption of a single, common and interoperable specification will reduce fragmentation and help the industry to take advantage of the fast-growing Internet of Things market, estimated to be worth US$1.1 trillion by 2020².

“It is clear that the industry is united behind this global standard which allows mobile operators to provide scalable, reliable and secure connectivity for a range of diverse services such as smart meters, traffic lights and home security, among many others,” said Alex Sinclair, Acting Director General and Chief Technology Officer, GSMA. “With commercial solutions already available today, we encourage additional operators and ecosystem players to adopt the specification in order to capitalise on the tremendous market opportunity enabled by the IoT.”

GSMA Intelligence research highlights that nearly 75 per cent³ of global M2M connections are now serviced by mobile operators that are deploying or are committed to the GSMA solution, underscoring the momentum behind the specification. Analyst firm Machina Research has also published research confirming that embedded SIM connections will account for 25 per cent of the embedded share of gross cellular additions by 2020 4 .

Profile Interoperability and Updated Test Specifications

The latest release of the GSMA Embedded SIM Specification includes a feature called ‘Profile Interoperability ’, which enables an operator to create a SIM Profile which can then be downloaded to any compliant eUICC regardless of the manufacturer. This feature will allow operators to easily connect a greater number of M2M devices, opening up the market, reducing fragmentation and providing additional commercial flexibility for original equipment manufacturers and M2M service providers. The GSMA has also released new test specifications to give assurance that products have the correct security levels and are compliant with the GSMA Embedded SIM Specification.

GSMA Embedded SIM at Mobile 360 Series Conferences

The GSMA’s Connected Living Programme will participate at the GSMA Mobile 360 Series of events taking place in Cape Town, Dubai, Atlanta and Brussels in the fourth quarter of 2015. Through workshops, panel discussions and keynote presentations, the Connected Living team will discuss the adoption of the GSMA Embedded SIM Specification, as well as the deployment of low power, wide area networks and the development of IoT network security. For further information on the Mobile 360 Series, visit www.mobile360series.com/.

For more information on the GSMA’s Embedded SIM please go to: http://www.gsma.com/connectedliving/connected-living-mobilising-the-internet-of-things/.

-ENDS-

Notes to Editors

1. Operators who have launched commercial solutions are: AT&T, Bell Canada, Etisalat, Indosat, NTT Docomo, Orange, Tele2, Telefonica | Vivo, Telefonica Group, Teliasonera and Vodafone

2. Machina Research (https://machinaresearch.com/)

3. According to GSMA Intelligence, as of Q2 2015, there are 273 million cellular M2M connections for all operators committed to launching the GSMA Embedded SIM Specification accounting for 75% of total global cellular M2M connections.

4. Machina Research (https://machinaresearch.com/)

About the GSMA

The GSMA represents the interests of mobile operators worldwide, uniting nearly 800 operators with more than 250 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces industry-leading events such as Mobile World Congress, Mobile World Congress Shanghai and the Mobile 360 Series conferences.

For more information, please visit the GSMA corporate website at www.gsma.com. Follow the GSMA on Twitter: @GSMA.

Contact information

Media:
For the GSMA
Charlie Meredith-Hardy
+44 7917 298428
CMeredith-Hardy@webershandwick.com
GSMA Press Office
pressoffice@gsma.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun

Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30Pressemelding

Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30Pressemelding

Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con

AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial9.12.2017 18:00Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the open-label, single-arm Phase II ACE-LY-004 clinical trial, which served as the basis for the recent US Food and Drug Administration (FDA) accelerated approval of Calquence (acalabrutinib). The findings were presented for the first time during an oral session at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA and demonstrate the safety profile and efficacy of acalabrutinib in the management of previously-treated mantle cell lymphoma (MCL). Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “The results presented for the first time to the medical community highlight the potential of Calquence as a treatment for people with relapsed or refractory mantle cell l

Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3.5 Year Follow-up Data of Imbruvica®▼(ibrutinib)9.12.2017 17:19Pressemelding

Today, Janssen-Cilag International NV (“Janssen”) announced results of a pooled analysis of relapsed/refractory (r/r) mantle cell lymphoma (MCL) patients treated with Imbruvica® (ibrutinib). The extended follow-up data demonstrated that patients treated with ibrutinib earlier (at first relapse) experienced the best clinical outcomes, both in terms of efficacy and tolerability. These data (abstract #151) were presented in an oral presentation at the 59th Annual American Society of Hematology (ASH) Meeting and Exposition in Atlanta, GA.1,2 Ibrutinib, a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, is jointly developed and commercialised by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company. “Data from this large clinical trial data set with extended follow-up support the early use of ibrutinib in patients with relapsed or refractory mantle cell lymphoma,” said Simo

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom